The latest price target for TransMedics Gr (NASDAQ:TMDX) was reported by Piper Sandler on October 29, 2024. The analyst firm set a price target for $180.00 expecting TMDX to rise to within 12 months (a possible 120.86% upside). 29 analyst firms have reported ratings in the last year.

The latest analyst rating for TransMedics Gr (NASDAQ:TMDX) was provided by Piper Sandler, and TransMedics Gr reiterated their overweight rating.

The last upgrade for TransMedics Group Inc happened on August 2, 2022 when JP Morgan raised their price target to $48. JP Morgan previously had a neutral for TransMedics Group Inc.

There is no last downgrade for TransMedics Gr.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransMedics Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransMedics Gr was filed on October 29, 2024 so you should expect the next rating to be made available sometime around October 29, 2025.

While ratings are subjective and will change, the latest TransMedics Gr (TMDX) rating was a reiterated with a price target of $180.00 to $180.00. The current price TransMedics Gr (TMDX) is trading at is $81.50, which is out of the analyst’s predicted range.